PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Results from CLASSICAL-Lung clinical trial were published in Clinical Cancer Research, a publication of the American Association for Cancer Research ( AACR ). CLASSICAL-Lung is a phase 1b/2 trial ev ...


Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free survival ( DFS ) in patients with epidermal growth factor receptor-muta ...


Doxofylline ( Ansimar ), an oral methylxanthine with bronchodilator and anti-inflammatory activities, offers a promising alternative to Theophylline due to its superior efficacy / safety profile. ...


Changes in the lung microbiome may help predict how well critically ill patients will respond to care. Specifically, patients with higher levels of lung bacteria one day after admission to the ICU In ...


In the phase III INBUILD trial Nintedanib ( Ofev ) has slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline in forced vital capacity ( FVC ...


Dupilumab ( Dupixent ), a fully human VelocImmune-derived anti-interleukin-4 ( IL-4 ) receptor alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, which are key drivers of type 2 inflamma ...


Antibodies against the IL-5 pathway have been developed for the treatment of late-onset eosinophilic corticosteroid-resistant asthma. However, the prevalence of severe asthma and the proportion of p ...


Theophylline can still have a role in the management of stable chronic obstructive pulmonary disease ( COPD ), but its use remains controversial, mainly due to its narrow therapeutic window. Doxof ...


The phase 2 ATLANTIC study has investigated the anti-PD-L1 antibody Durvalumab ( Imfinzi ) in heavily pretreated patients with advanced non-small cell lung cancer ( NSCLC ). Researchers have repor ...


CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy in advanced non-small cell lung cancer ( NSCLC ) ...


ALTA trial has evaluated 2 doses of the ALK inhibitor Brigatinib post-Crizotinib. Overall objective response rate ( ORR ) contains both CNS and extra-CNS target lesion data. In ALTA, stratification ...


CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy in advanced non-small cell lung cancer ( NSCLC ). The stud ...


Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ( NSCLC ) continue to develop resistance and CNS metastases become more d ...


Small-cell lung cancer ( SCLC ) is an aggressive lung cancer with high rate of relapse following initial treatment; immunotherapy holds potential as a novel treatment option for this disease. The an ...


Alectinib ( Alecensa ) has proven systemic and CNS efficacy in patients with ALK+ aNSCLC ( advanced non-small cell lung cancer ) ( ALEX trial ). T umor cell death caused by Alectinib may release anti ...